Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA CAR-T cells (University of California, San Francisco)
- Development stage
- Unknown
- Lead developer
- University of California, San Francisco
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-BCMA CAR-T cells (also known as 1XX BCMA CAR-T cells) is an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Thomas Martin, MD, at the University of California, San Francisco (UCSF). The therapy involves collecting a patient's own T cells and using CRISPR-Cas9 technology to genetically engineer them to express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA). BCMA is a protein highly and selectively expressed on malignant plasma cells in multiple myeloma. Following lymphodepleting chemotherapy with fludarabine and cyclophosphamide, the engineered cells are expanded and infused back into the patient to induce targeted cell lysis of myeloma cells. The drug is currently being evaluated in Phase 1 clinical trials for the treatment of relapsed or refractory multiple myeloma (RRMM).
- Other names
- anti-BCMA CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-BCMA CAR-T cells (University of California, San Francisco).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA CAR-T cells (University of California, San Francisco).